Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ovalbumin + PLGA
- Development stage
- Preclinical
- Lead developer
- UT Health San Antonio
- Modality
- Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intravenous, Subcutaneous, Intratumoral
01
Overview
Ovalbumin + PLGA refers to a nanoparticle-based vaccine delivery system where the model antigen ovalbumin (OVA) is encapsulated within poly(lactic-co-glycolic acid) (PLGA) nanoparticles. In the context of the provided research, these nanoparticles are dual-loaded with alpha-galactosylceramide (alpha-GalCer), a glycolipid agonist that binds to CD1d to activate invariant natural killer T (iNKT) cells. This delivery platform is designed to enhance anti-tumor immunity by promoting the production of pro-inflammatory cytokines like IFN-gamma and facilitating the presentation of tumor-associated antigens. Preclinical studies in melanoma models have demonstrated that this formulation can decrease tumor growth and increase survival, particularly when used in combination with immune checkpoint inhibitors like anti-PD-1 and anti-CTLA-4.
- Other names
- OVA-loaded PLGA nanoparticlesalpha-GalCer/OVA-PLGA nanoparticlesovalbumin-loaded poly(lactic-co-glycolic acid) nanoparticles
02
Targets
H-2Kb-SIINFEKL (Mouse MHC class I antigen H-2Kb (H-2Kb) presenting ovalbumin-derived peptide SIINFEKL)CD1D (Tumor-associated macrophage/myeloid-derived suppressor cell CD1d complex)
Beyond the preview
Go deeper on ovalbumin + PLGA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ovalbumin + PLGA.